首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1619271

核子醫學市場規模、佔有率、成長分析，按診斷劑、治療劑、應用、最終用戶、地區 - 產業預測，2024-2031

Nuclear Medicine Market Size, Share, Growth Analysis, By Diagnostics (SPECT, PET), By Therapeutics (Alpha Emitters, Beta Emitters), By Application, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球核醫市場規模為91億美元，從2023年的101.7億美元成長到2031年的248.3億美元，預計在預測期（2024-2031）複合年成長率為11.8%。

由於強大的產品平臺和政府支持的旨在提高先進診斷和治療選擇機會的舉措，核醫市場正在不斷成長。這領域結合了多個領域，利用放射性藥物評估器官功能和結構，對於甲狀腺癌等疾病的早期發現極為重要。 Betaltin、 Omburtamab和 Ytttrium-90 微球等主要產品目前正處於臨床試驗階段。儘管面臨新冠肺炎 (COVID-19) 大流行帶來的挑戰，被列為基本服務的核子反應爐仍在繼續運行，提供關鍵的醫療用品。美國癌症協會強調核醫學的緊迫性，前列腺癌的高盛行率和 FDA 最近核准Pluvicto 用於治療轉移病例證明了這一點，並強調了這一醫學領域的重要性正在增加。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 西班牙
- 法國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2023）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
- 收益與前一年同期比較（2021-2023）

主要企業簡介

GE Healthcare
Curium Pharma
Novartis
Cardinal Health
Lantheus Medical Imaging
Bracco Imaging SPA
Jubilant Life Sciences Ltd
Nordion（Canada）, Inc.
Siemens Healthineers
Bayer AG
Eckert & Ziegler
Telix Pharmaceuticals
NorthStar Medical Radioisotopes, LLC
Shine Medical Technologies
Isotopia Molecular Imaging Ltd.
Institute of Isotopes Co., Ltd.
Mediso Ltd.
NTP Radioisotopes SOC Ltd.
ITM Isotopen Technologien Munchen AG
Radiopharm Theranostics

結論和建議

簡介目錄

Product Code: SQMIG35I2285

Global Nuclear Medicine Market size was valued at USD 9.1 billion in 2022 and is poised to grow from USD 10.17 billion in 2023 to USD 24.83 billion by 2031, growing at a CAGR of 11.8% during the forecast period (2024-2031).

The nuclear medicine market is experiencing growth, driven by a strong product pipeline and supportive government initiatives aimed at enhancing accessibility to advanced diagnostic and therapeutic options. This field combines multiple disciplines, utilizing radiopharmaceuticals to assess organ function and structure, crucial for early disease detection such as thyroid cancer. Key products, including betalutin, omburtamab, and yttrium-90 microspheres, are currently in clinical trials. Despite the challenges posed by the COVID-19 pandemic, nuclear reactors, classified as essential services, continued operations to provide critical medicines. The American Cancer Society highlights the urgency of nuclear medicine, as evidenced by the significant incidence of prostate cancer and the recent FDA approval of Pluvicto for metastatic cases, underscoring the growing importance of this medical specialty.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nuclear Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nuclear Medicine Market Segmental Analysis

Global Nuclear Medicine Market is segmented by diagnostics, therapeutics, application, end user and region. Based on diagnostics, the market is segmented into SPECT (single photon emission computed tomography) (technetium-99m, thallium-201, iodine-123, others) and PET (positron emission tomography) (fluorine-18, rubidium-82, others). Based on therapeutics, the market is segmented into alpha emitters (radium-223, actinium-225), beta emitters (iodine-131, yttrium-90, lutetium-177) and brachytherapy isotopes (iodine-125, palladium-103, cesium-131). Based on application, the market is segmented into oncology (thyroid cancer, bone metastasis, lymphoma), cardiology (myocardial perfusion imaging, ventricular function imaging), neurology (brain imaging, alzheimer's disease) and others (gastroenterology, nephrology). Based on end user, the market is segmented into hospitals, diagnostic centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nuclear Medicine Market

The Global Nuclear Medicine market is significantly driven by the increasing incidence and prevalence of cancer and cardiovascular disease (CVD). The World Health Organization reported that cancer was the leading cause of death in 2020, resulting in nearly 10 million fatalities, with projections indicating that 19.3 million new cancer cases will be diagnosed annually by 2025. Furthermore, in 2019, CVD was responsible for 17.9 million deaths, making up 32% of global mortality, and this figure is anticipated to climb to 23.3 million by 2030. The critical role of nuclear medicine in early diagnosis and treatment of these diseases is poised to propel market growth as demand for effective medical interventions rises.

Restraints in the Global Nuclear Medicine Market

The global nuclear medicine market faces several constraints, primarily due to the rising adoption of alternative diagnostic methods for various illnesses. While nuclear medicine techniques like PET scans are commonly used for cancer detection and cardiovascular imaging, technologies such as MRI and CT scans are increasingly favored, especially in developing countries. These alternatives are often more cost-effective, leading to greater utilization as they benefit from supportive reimbursement policies. Consequently, the shift towards these imaging modalities is likely to hinder the growth of the nuclear medicine market in the coming years, as healthcare providers opt for these less expensive diagnostic options.

Market Trends of the Global Nuclear Medicine Market

The global nuclear medicine market is witnessing a significant upward trend, driven by ongoing advancements in nuclear medicine therapies. Companies are increasingly focused on developing innovative therapies that showcase superior clinical efficacy compared to traditional treatment options, particularly in oncology and other high-burden diseases. This surge in demand is bolstered by regulatory endorsements, such as the US FDA's approval for Curium's Phase-III trial of lutetium Lu 177 PSMA I&T, a promising radiopharmaceutical targeting prostate cancer. Additionally, the emergence of new therapeutic agents by various market players is further stimulating growth, reflecting a robust pipeline geared toward addressing diverse medical conditions and enhancing patient care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis
Case Studies

Global Nuclear Medicine Market Size by Diagnostics & CAGR (2024-2031)

Market Overview
SPECT (Single Photon Emission Computed Tomography)
- Technetium-99m
- Thallium-201
- Iodine-123
- Others
PET (Positron Emission Tomography)
- Fluorine-18
- Rubidium-82
- Others

Global Nuclear Medicine Market Size by Therapeutics & CAGR (2024-2031)

Market Overview
Alpha Emitters
- Radium-223
- Actinium-225
Beta Emitters
- Iodine-131
- Yttrium-90
- Lutetium-177
Brachytherapy Isotopes
- Iodine-125
- Palladium-103
- Cesium-131

Global Nuclear Medicine Market Size by Applications & CAGR (2024-2031)

Market Overview
Oncology
- Thyroid Cancer
- Bone Metastasis
- Lymphoma
Cardiology
- Myocardial Perfusion Imaging
- Ventricular Function Imaging
Neurology
- Brain Imaging
- Alzheimer's Disease
Others
- Gastroenterology
- Nephrology

Global Nuclear Medicine Market Size by End User & CAGR (2024-2031)

Market Overview
Hospitals
Diagnostic Centers
Research Institutes

Global Nuclear Medicine Market Size & CAGR (2024-2031)

North America, (Diagnostics, Therapeutics, Applications, End User)
- US
- Canada
Europe, (Diagnostics, Therapeutics, Applications, End User)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific, (Diagnostics, Therapeutics, Applications, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America, (Diagnostics, Therapeutics, Applications, End User)
- Brazil
- Rest of Latin America
Middle East & Africa, (Diagnostics, Therapeutics, Applications, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

GE Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curium Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cardinal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Medical Imaging
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco Imaging S.P.A
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Life Sciences Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nordion (Canada), Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eckert & Ziegler
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Telix Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NorthStar Medical Radioisotopes, LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shine Medical Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Isotopia Molecular Imaging Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Institute of Isotopes Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mediso Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NTP Radioisotopes SOC Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ITM Isotopen Technologien Munchen AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radiopharm Theranostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments